Search Results
Search for other papers by D Campana in
Google Scholar
PubMed
Search for other papers by F Nori in
Google Scholar
PubMed
Search for other papers by R Pezzilli in
Google Scholar
PubMed
Search for other papers by L Piscitelli in
Google Scholar
PubMed
Search for other papers by D Santini in
Google Scholar
PubMed
Search for other papers by E Brocchi in
Google Scholar
PubMed
Search for other papers by R Corinaldesi in
Google Scholar
PubMed
Search for other papers by P Tomassetti in
Google Scholar
PubMed
somatostatin analog treatment in type I gastric endocrine tumors. Patients and methods From January 2000 to December 2006, all patients admitted to our unit with gastric endocrine tumors underwent the following study protocol. A baseline visit was made in which
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Antonio Facciorusso in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Francesca Corti in
Google Scholar
PubMed
Search for other papers by Monica Niger in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Tommaso Cascella in
Google Scholar
PubMed
Search for other papers by Iolanda Pulice in
Google Scholar
PubMed
Search for other papers by Lavinia Biamonte in
Google Scholar
PubMed
Search for other papers by Simonetta Papa in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Aashni Shah in
Google Scholar
PubMed
Search for other papers by Rodolfo Sacco in
Google Scholar
PubMed
Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy
Search for other papers by Filippo de Braud in
Google Scholar
PubMed
). Pharmacological treatment of GEP NETs comprises somatostatin analogs (SSAs; octreotide (OCT) long-acting release and lanreotide (LAN) autogel), chemotherapy, peptide receptor radiotherapy and targeted therapy with everolimus or sunitinib ( Oronsky et al. 2017
Search for other papers by Iulia Potorac in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Sophie Borot in
Google Scholar
PubMed
Search for other papers by Mona Sahnoun-Fathallah in
Google Scholar
PubMed
Search for other papers by Frederic Castinetti in
Google Scholar
PubMed
Search for other papers by France Devuyst in
Google Scholar
PubMed
Search for other papers by Marie-Lise Jaffrain-Rea in
Google Scholar
PubMed
Search for other papers by Claire Briet in
Google Scholar
PubMed
Search for other papers by Florina Luca in
Google Scholar
PubMed
Search for other papers by Marion Lapoirie in
Google Scholar
PubMed
Search for other papers by Flavius Zoicas in
Google Scholar
PubMed
Search for other papers by Isabelle Simoneau in
Google Scholar
PubMed
Search for other papers by Alpha M Diallo in
Google Scholar
PubMed
Search for other papers by Ammar Muhammad in
Google Scholar
PubMed
Search for other papers by Fahrettin Kelestimur in
Google Scholar
PubMed
Search for other papers by Elena Nazzari in
Google Scholar
PubMed
Search for other papers by Rogelio Garcia Centeno in
Google Scholar
PubMed
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
Search for other papers by Vaclav Hana in
Google Scholar
PubMed
Search for other papers by Véronique Pascal-Vigneron in
Google Scholar
PubMed
Search for other papers by Irena Ilovayskaya in
Google Scholar
PubMed
Search for other papers by Farida Nasybullina in
Google Scholar
PubMed
Search for other papers by Samia Achir in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Brigitte Delemer in
Google Scholar
PubMed
Search for other papers by Jean-Michel Petit in
Google Scholar
PubMed
Search for other papers by Christof Schöfl in
Google Scholar
PubMed
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Bernard Goichot in
Google Scholar
PubMed
Search for other papers by Patrice Rodien in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Franck Schillo in
Google Scholar
PubMed
Search for other papers by Luaba Tshibanda in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
: clinical profile and therapeutic responses . Endocrine-Related Cancer 22 353 – 367 . ( doi:10.1530/ERC-15-0038 ) Bevan JS 2005 Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly . Journal of Clinical
Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Alessandra Dicitore in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Sergio Di Molfetta in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
represented by surgery followed by medical management, such as somatostatin analogs (SSAs), mTOR inhibitors, tyrosine kinase inhibitors, chemotherapy and peptide receptor radionuclide therapy. However, new treatment options to further improve survival outcomes
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
Search for other papers by Boen L Kam in
Google Scholar
PubMed
Search for other papers by Martijn van Essen in
Google Scholar
PubMed
Search for other papers by Jaap J M Teunissen in
Google Scholar
PubMed
Search for other papers by Casper H J van Eijck in
Google Scholar
PubMed
Search for other papers by Roelf Valkema in
Google Scholar
PubMed
Search for other papers by Marion de Jong in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Eric P Krenning in
Google Scholar
PubMed
Introduction Peptide receptor scintigraphy in man started with the in vivo demonstration of somatostatin receptor-positive tumors in patients using a radioiodinated somatostatin analog ( Krenning et al . 1989 ). Later, other radiolabeled
Search for other papers by Shoucheng Ning in
Google Scholar
PubMed
Search for other papers by Susan J Knox in
Google Scholar
PubMed
Search for other papers by Griffith R Harsh in
Google Scholar
PubMed
Search for other papers by Michael D Culler in
Google Scholar
PubMed
Departments of, Radiation Oncology, Neurosurgery, Medicine, IPSEN
Search for other papers by Laurence Katznelson in
Google Scholar
PubMed
Introduction Somatostatin is a peptide hormone that exerts its biologic activity, including inhibition of hormone secretion, by interacting with a family of G protein receptors. Administration of somatostatin analogs, such as lanreotide and
Search for other papers by E Ferrante in
Google Scholar
PubMed
Search for other papers by C Pellegrini in
Google Scholar
PubMed
Search for other papers by S Bondioni in
Google Scholar
PubMed
Search for other papers by E Peverelli in
Google Scholar
PubMed
Search for other papers by M Locatelli in
Google Scholar
PubMed
Search for other papers by P Gelmini in
Google Scholar
PubMed
Search for other papers by P Luciani in
Google Scholar
PubMed
Search for other papers by A Peri in
Google Scholar
PubMed
Search for other papers by G Mantovani in
Google Scholar
PubMed
Search for other papers by S Bosari in
Google Scholar
PubMed
Search for other papers by P Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by A Spada in
Google Scholar
PubMed
Search for other papers by A Lania in
Google Scholar
PubMed
, largely depending on the SST subtype and the cell system considered ( Hofland et al. 1999 , Benali et al. 2000 ). Due to the physiological actions of somatostatin, long acting analogs that bind with high affinity SST2 and, to a less extent, SST5, such
Search for other papers by Mintallah Haider in
Google Scholar
PubMed
Search for other papers by Satya Das in
Google Scholar
PubMed
Search for other papers by Taymeyah Al-Toubah in
Google Scholar
PubMed
Search for other papers by Eleonora Pelle in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
, Remes et al. 2019 ). An emerging class of therapeutics for patients with WD NETs consists of radiolabeled somatostatin analogs (SSA), which fall under the broader therapeutic class of peptide receptor radionuclide therapy (PRRT). PRRT enables the
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Alexandru Saveanu in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Mihaela Muresan in
Google Scholar
PubMed
Search for other papers by Catherine De Micco in
Google Scholar
PubMed
Search for other papers by David Taieb in
Google Scholar
PubMed
Search for other papers by Anne-Laure Germanetti in
Google Scholar
PubMed
Search for other papers by Frederic Sebag in
Google Scholar
PubMed
Search for other papers by Jean-François Henry in
Google Scholar
PubMed
Search for other papers by Laurent Brunaud in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Alain Enjalbert in
Google Scholar
PubMed
Search for other papers by Georges Weryha in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Anne Barlier in
Google Scholar
PubMed
et al . 2009 ). The various effects of somatostatin and its analogs are mediated through five-membrane G protein-coupled receptors: somatostatin receptor subtypes 1–5 (sst 1–5 ). The presence of sst in PCC/PGL has been demonstrated by ligand binding
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by David P Ryan in
Google Scholar
PubMed
Search for other papers by Andrew X Zhu in
Google Scholar
PubMed
Search for other papers by Thomas A Abrams in
Google Scholar
PubMed
Search for other papers by Brian M Wolpin in
Google Scholar
PubMed
Search for other papers by Paige Malinowski in
Google Scholar
PubMed
Search for other papers by Eileen M Regan in
Google Scholar
PubMed
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
Introduction Somatostatin analogs have been widely used in patients with advanced neuroendocrine tumors for the treatment of carcinoid syndrome and related symptoms of hormone hypersecretion ( Kvols et al . 1986 , di Bartolomeo et al . 1996